AMGEN Inc. (NASDAQ:AMGN) finished Friday with a subtraction of -$2.06 to close at $268.76, a downside of -0.76 percent. An average of 2,190,700 shares of common stock have been traded in the last five days. There was a gain of $1.06 in the past week, and it reached a new high 17 times over the past 12 months. The last 20 days have seen an average of 2,353,220 shares traded, while the 50-day average volume stands at 2,503,982.
AMGN stock has increased by 4.22% in the last month. The company shares reached their 1-month lowest point of $248.38 on 09/06/23. With the stock rallying to its 52-week high on 01/11/23, shares of the company touched a low of $211.71 and a high of $296.67 in 52 weeks. It has reached a new high 5 times so far this year and achieved 2.33% or $6.12 in price. In spite of this, the price is down -9.41% from the 52-week high.
Insider Transactions
AMGN stock investors should be aware that AMGEN Inc. (AMGN) stock had its last reported insider trading activity 51 days ago on Sep 19. In this transaction, the insider spent $2,508,306. SVP, Business Development, Khosla Rachna, disposed of 387 shares at a price of $292.90 on Nov 09. The insider now owns more than $113,352 worth of shares. Prior to that, SVP & CCO Grygiel Nancy A. went on to Sale 545 shares at $293.54 each on Nov 08. An amount of $159,977 was transacted.
Valuation Metrics
AMGEN Inc. (AMGN) has a trailing price-to-earnings (P/E) ratio of 18.12. The stock’s beta is 0.59. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.46, the price-to-book (PB) ratio at 21.20, and the price-to-cash flow ratio at 14.84.
The company has a payout ratio of 64.07%. The company’s most recent quarterly dividend payment was $2.13 a share, without any change from last year. Its latest increase dividend $0.19 reported on Monday December 12 2022.
Financial Health
The quick ratio of AMGEN Inc. for the three months ended June 29 was 2.48, and the current ratio was 2.77, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 8.76 and a total debt to equity ratio of 9.08 for the quarter ending June 29. Its gross profit as reported stood at $19.92 billion compared to revenue of $26.32 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, AMGEN Inc.’s return on assets was 10.67%.
Earnings Surprise
For the three-month period that ended June 29, AMGEN Inc. had $59.38 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.38 billion in the quarter, while revenues of $2.84 billion were grew 4.5%. The analyst consensus anticipated AMGEN Inc.’s latest quarter earnings to come in at $4.49 per share, but it turned out to be $5, a 11.40% surprise. For the quarter, EBITDA amounted to $3.58 billion. Shareholders own equity worth $534.9 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at AMGEN Inc. (AMGN) price momentum. RSI 9-day as of the close on 29 September was 60.19%, suggesting the stock is Neutral, with historical volatility in this time frame at 16.29%.
As of today, AMGN’s price is $268.89 +0.40% or $1.06 from its 5-day moving average. AMGN is currently trading +4.85% higher than its 20-day SMA and +14.55% higher than its 100-day SMA. However, the stock’s current price level is +15.23% above the SMA50 and -2.90% below the SMA200.
The stochastic %K and %D were 76.37% and 77.98%, respectively, and the average true range (ATR) was 4.63. With the 14-day stochastic at 70.77% and the average true range at 4.60, the RSI (14) stands at 60.99%. The stock has reached 0.93 on the 9-day MACD Oscillator while the 14-day reading was at 3.73.
Analyst Ratings
HSBC Securities launched coverage on AMGEN Inc. (NASDAQ: AMGN) in its analyst report released on September 06, 2023. The firm assigned the stock a Buy rating. The consensus rating for AMGEN Inc. (AMGN) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell AMGN, while 12 suggest investors hold. There are 2 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 10 others rate it as a “buy”.
